Search results
18 gru 2014 · Results: Compared with alternative formulations, leuprorelin solid implants had potential annual cost savings/1000 patients of €353,000 (EU5) and €699,000 (Sweden; 1-month formulations), and €259,000 (EU5) and €300,000 (Sweden; 3-month formulations).
Leuprorelin acetate Atrigel was found to be clinically more effective and cost-saving than other LHRH agonists in the intermediate- and high-risk groups, regardless of testosterone suppression targets.
11 sie 2017 · This study aimed to evaluate the economic value for leuprorelin acetate 6-month depot compared with leuprorelin acetate 3-month depot from societal perspective in Japanese prostate cancer patients. In the cost analysis, we estimated the reduction in direct and indirect costs as well as intangible costs saved by having one less injection.
16 sie 2017 · We conducted a cost analysis for having one less injection of leuprorelin acetate in Japanese prostate cancer patients to evaluate the costs of leuprorelin acetate 6-month depot formulation compared with the 3-month depot formulation.
18 gru 2014 · Based on modelling with meta-analysis of comparative survival data, leuprorelin 22.5 mg was the most cost-effective treatment of the available depot formulation LHRH agonists.
Intangible costs saved by using a 6-month depot formulation instead of a 3-month depot formulation for the injection of leuprorelin acetate were estimated to be JPY 19,872, including the values for a reduction in pain (JPY 3,131), injection site reactions (JPY 11,545), waiting time (JPY 9,479), and subtracting the value of medical consultation ...
leuprorelin acetate in Japanese prostate cancer patients to evaluate the costs of leuprorelin acetate 6-month depot for-mulation compared with the 3-month depot formulation. The cost analysis consisted of three elements: direct costs reduc-tion, indirect costs reduction, and intangible costs saving.
